BRAF, BRAFV600E, BRAFV600E colorectal cancer models, BRAFi, CDK4/6, CDK4/6i, EGFR, EGFR-mutant, EGFR-mutant lung, EGFR-mutant lung cancer, EGFRi, ERK, KRAS mutations, KRASG12C, KRASG12C cancer cells, KRASG12Ci, MAPK, MEK, PD-1, RAS, RAS isoforms, RTK, RTK- and MAPK-driven cancers, RTKs, Receptor Tyrosine Kinase, SHP2, TNO155, Tyrosine, anti-, anti-PD-1 antibody, cancer, cancer cells, colony-stimulating factor 1 receptor, colorectal cancer, immunosuppressive tumor-associated macrophages, lung and colorectal cancer, nazartinib, patient, programmed cell death-1, receptor tyrosine kinase, ribociclib, tumor, tumors, tyrosine, wild-type KRAS